Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)
Launched by CASE COMPREHENSIVE CANCER CENTER · Jan 31, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The MINDSET trial is a study designed to help reduce feelings of depression in people who have recently finished treatment for breast, prostate, or colorectal cancer. This program will use mindfulness techniques, which are ways to help individuals focus on the present moment and manage their thoughts and feelings. The goal is to see if sending these mindfulness exercises via text messages can effectively support individuals experiencing mild to moderate depressive symptoms after their cancer treatment.
To participate in this trial, you must have been diagnosed with stage 0 to III breast, prostate, or colorectal cancer and completed your primary treatment within the last two years. You should also be experiencing some depressive symptoms, but they need to be mild to moderate. Participants will need a device like a phone or computer to receive the text messages and should be comfortable reading and speaking in English. The trial is not yet recruiting participants, but if you meet the criteria, it could be a great opportunity for support in managing your mental health during recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Self-reported mild to moderately-severe symptoms of depression (score 5-19 on PHQ-9).
- • 2. A diagnosis of stage 0-III breast, prostate, or colorectal cancer.
- • 3. Completion of primary cancer treatment within 2 years (excludes hormone therapy).
- • 4. An ability to provide informed consent.
- • 5. An ability to read and speak English.
- • 6. Access to a web-enabled device (phone, tablet, computer).
- Exclusion Criteria:
- • 1. Self-reported minimal and severe depressive symptoms (\<4 and \> 20 on PHQ-9).
- • 2. Self-reported suicidal ideation (\>1 on item 9 PHQ-9).
- • 3. Another psychological, medical, or other condition/issue determined that necessitates priority treatment and/or that would interfere with participation (e.g., schizophrenia, borderline personality disorder)
- • 4. Current or recent substance abuse/dependence.
- • 5. Stage IV cancer diagnosis.
- • 6. A cancer recurrence actively requiring treatment.
- • 7. Self-reported active mindfulness practice.
- • 8. Prior participation in a formal mindfulness program (e.g., MBCT, Mindfulness-Based Stress Reduction Program, Mindfulness-Based Cancer Recovery
About Case Comprehensive Cancer Center
Case Comprehensive Cancer Center is a leading academic research institution dedicated to advancing cancer care through innovative clinical trials and cutting-edge research. As a National Cancer Institute-designated Comprehensive Cancer Center, it integrates multidisciplinary approaches to cancer prevention, diagnosis, and treatment, fostering collaboration among clinicians, researchers, and patients. The center is committed to translating scientific discoveries into effective therapies, enhancing patient outcomes, and contributing to the global body of cancer knowledge. With a robust portfolio of clinical trials, Case Comprehensive Cancer Center aims to address the unmet needs of cancer patients and drive progress in the fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cleveland, Ohio, United States
Patients applied
Trial Officials
Chelsea Siwik, PhD
Principal Investigator
Case Comprehensive Cancer Center, Cleveland Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported